Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
CL and KW conducted to the data analysis and manuscript drafting for this work
In November 2023, it was approved again under the brand name Zepbound for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition
This dual action can influence appetite, energy metabolism, and blood sugar regulation in potentially different ways than a GLP-1-only drug, which may translate to greater average weight loss for some patients
These clinical trial figures may differ from real-world experience
Mistake 5: contamination from multi-use brand pens Attempting to microdose using brand-name Zepbound or Mounjaro pens by withdrawing small amounts across multiple sessions creates contamination risk
